MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM

This adaptive platform trial is testing multiple new treatments for relapsed or refractory multiple myeloma (a blood cancer that has come back or stopped responding to treatment) in patients who have already tried standard drug classes. **You may be eligible if...** - You are 18 or older - You have multiple myeloma that has been exposed to, relapsed from, or become intolerant to a proteasome inhibitor, an immunomodulatory drug (IMiD), and an anti-CD38 antibody - You have had between 1 and 4 prior lines of treatment - You have measurable disease in the blood, urine, or on imaging - You are in generally good health (ECOG 0-2) - Your blood counts and organ function meet required thresholds **You may NOT be eligible if...** - You have received prior BCMA-directed therapy within the last 6 months (a washout period is required) - You do not meet blood count or organ function requirements Talk to your doctor to see if this trial is right for you.